Research ExplorerPublicationsCircumvention of methotrexate resistance in childhood leukem...

Circumvention of methotrexate resistance in childhood leukemia subtypes by rationally designed antifolates.

Standard

Circumvention of methotrexate resistance in childhood leukemia subtypes by rationally designed antifolates. / Rots, M G; Pieters, R; Peters, G J; van Zantwijk, C H; Mauritz, R; Noordhuis, P; Willey, J C; Hählen, K; Creutzig, U; Janka-Schaub, Gritta; Kaspers, G J; Veerman, A J; Jansen, G.

In: BLOOD, Vol. 94, No. 9, 9, 1999, p. 3121-3128.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Rots, MG, Pieters, R, Peters, GJ, van Zantwijk, CH, Mauritz, R, Noordhuis, P, Willey, JC, Hählen, K, Creutzig, U, Janka-Schaub, G, Kaspers, GJ, Veerman, AJ & Jansen, G 1999, 'Circumvention of methotrexate resistance in childhood leukemia subtypes by rationally designed antifolates.', BLOOD, vol. 94, no. 9, 9, pp. 3121-3128. <http://www.ncbi.nlm.nih.gov/pubmed/10556198?dopt=Citation>

APA

Rots, M. G., Pieters, R., Peters, G. J., van Zantwijk, C. H., Mauritz, R., Noordhuis, P., Willey, J. C., Hählen, K., Creutzig, U., Janka-Schaub, G., Kaspers, G. J., Veerman, A. J., & Jansen, G. (1999). Circumvention of methotrexate resistance in childhood leukemia subtypes by rationally designed antifolates. BLOOD, 94(9), 3121-3128. [9]. http://www.ncbi.nlm.nih.gov/pubmed/10556198?dopt=Citation

Vancouver

Rots MG, Pieters R, Peters GJ, van Zantwijk CH, Mauritz R, Noordhuis P et al. Circumvention of methotrexate resistance in childhood leukemia subtypes by rationally designed antifolates. BLOOD. 1999;94(9):3121-3128. 9.

Bibtex

@article{b6e2e2c8d7a6457890f5b84216b3f95b,
title = "Circumvention of methotrexate resistance in childhood leukemia subtypes by rationally designed antifolates.",
abstract = "Cellular methotrexate (MTX) resistance may cause treatment failure in childhood common/preB-acute lymphoblastic leukemia (c/preB-ALL), T-lineage ALL (T-ALL), and acute myeloid leukemia (AML). The ex vivo potency of several antifolates (MTX, trimetrexate [TMQ], GW1843U89, multitargeted antifolate [MTA], Raltitrexed, and ZD9331) was studied via in situ inhibition of thymidylate synthase (TS). After short-term exposure, relapsed c/preB-ALL (rALL, n = 21), T-ALL (n = 22), and AML (n = 22) were 3-fold, 10-fold, and 6-fold less sensitive to MTX (P",
author = "Rots, {M G} and R Pieters and Peters, {G J} and {van Zantwijk}, {C H} and R Mauritz and P Noordhuis and Willey, {J C} and K H{\"a}hlen and U Creutzig and Gritta Janka-Schaub and Kaspers, {G J} and Veerman, {A J} and G Jansen",
year = "1999",
language = "Deutsch",
volume = "94",
pages = "3121--3128",
journal = "BLOOD",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "9",

}

RIS

TY - JOUR

T1 - Circumvention of methotrexate resistance in childhood leukemia subtypes by rationally designed antifolates.

AU - Rots, M G

AU - Pieters, R

AU - Peters, G J

AU - van Zantwijk, C H

AU - Mauritz, R

AU - Noordhuis, P

AU - Willey, J C

AU - Hählen, K

AU - Creutzig, U

AU - Janka-Schaub, Gritta

AU - Kaspers, G J

AU - Veerman, A J

AU - Jansen, G

PY - 1999

Y1 - 1999

N2 - Cellular methotrexate (MTX) resistance may cause treatment failure in childhood common/preB-acute lymphoblastic leukemia (c/preB-ALL), T-lineage ALL (T-ALL), and acute myeloid leukemia (AML). The ex vivo potency of several antifolates (MTX, trimetrexate [TMQ], GW1843U89, multitargeted antifolate [MTA], Raltitrexed, and ZD9331) was studied via in situ inhibition of thymidylate synthase (TS). After short-term exposure, relapsed c/preB-ALL (rALL, n = 21), T-ALL (n = 22), and AML (n = 22) were 3-fold, 10-fold, and 6-fold less sensitive to MTX (P

AB - Cellular methotrexate (MTX) resistance may cause treatment failure in childhood common/preB-acute lymphoblastic leukemia (c/preB-ALL), T-lineage ALL (T-ALL), and acute myeloid leukemia (AML). The ex vivo potency of several antifolates (MTX, trimetrexate [TMQ], GW1843U89, multitargeted antifolate [MTA], Raltitrexed, and ZD9331) was studied via in situ inhibition of thymidylate synthase (TS). After short-term exposure, relapsed c/preB-ALL (rALL, n = 21), T-ALL (n = 22), and AML (n = 22) were 3-fold, 10-fold, and 6-fold less sensitive to MTX (P

M3 - SCORING: Zeitschriftenaufsatz

VL - 94

SP - 3121

EP - 3128

JO - BLOOD

JF - BLOOD

SN - 0006-4971

IS - 9

M1 - 9

ER -